Granulocytapheresis in patients with refractory ocular behcet's disease

Kenichi Namba, Koh Hei Sonoda, Hirokuni Kitamei, Kenji Shiratori, Akiko Ariyama, Kazuya Iwabuchi, Kazunori Onoé, Abby R. Saniabadi, Shoichi Inaba, Tatsuro Ishibashi, Shigeaki Ohno

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Intraocular inflammation (uveoretinitis) is one major complication of Behcet's disease (BD) and responds poorly to drug therapy. This open prospective study was to assess the efficacy of selective granulocytapheresis in patients with refractory uveoretinitis of BD. Fourteen patients aged 20-56 years were treated. Granulocytapheresis was done with an Adacolumn filled with cellulose acetate leucocyte carries or beads that adsorb granulocytes and monocytes from the blood in the column. Each patient received 5 Adacolumn sessions at one session/week over 5 consecutive weeks. The study was designed to allow each patient to serve as his or her own control. The total numbers of ocular attacks (OA) were monitored for 6 months before and after 5 Adacolumn sessions. The number of OA (mean ± SD) per patient for the 6 months before Adacolumn was 4.21 ± 1.6 and for the 6 months post Adacolumn was 2.93 ± 1.39 (P = 0.0275). Nine patients (64%) improved and 5 did not change or worsened. Further, for a sub-group (n = 7) with duration of BD ≥5 years, the number of OA were 4.71 ± 1.89 for the first 6 months and 2.29 ± 1.38 for the second 6 months (P = 0.0054). The corresponding values for a sub-group (n = 7) with duration of BD<5 years were 3.71 ± 1.25 and 3.57 ± 1.13, indicating that patients with long duration of BD are better responders. We conclude that granulocytapheresis might be effective and safe for patients with refractory ocular BD. Further studies are necessary to fully evaluate the clinical efficacy of granulocytapheresis for BD.

Original languageEnglish
Pages (from-to)121-128
Number of pages8
JournalJournal of Clinical Apheresis
Volume21
Issue number2
DOIs
Publication statusPublished - Jul 1 2006

Fingerprint

Eye Diseases
Behcet Syndrome
Granulocytes
Monocytes
Leukocytes
Prospective Studies
Inflammation
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Namba, K., Sonoda, K. H., Kitamei, H., Shiratori, K., Ariyama, A., Iwabuchi, K., ... Ohno, S. (2006). Granulocytapheresis in patients with refractory ocular behcet's disease. Journal of Clinical Apheresis, 21(2), 121-128. https://doi.org/10.1002/jca.20076

Granulocytapheresis in patients with refractory ocular behcet's disease. / Namba, Kenichi; Sonoda, Koh Hei; Kitamei, Hirokuni; Shiratori, Kenji; Ariyama, Akiko; Iwabuchi, Kazuya; Onoé, Kazunori; Saniabadi, Abby R.; Inaba, Shoichi; Ishibashi, Tatsuro; Ohno, Shigeaki.

In: Journal of Clinical Apheresis, Vol. 21, No. 2, 01.07.2006, p. 121-128.

Research output: Contribution to journalArticle

Namba, K, Sonoda, KH, Kitamei, H, Shiratori, K, Ariyama, A, Iwabuchi, K, Onoé, K, Saniabadi, AR, Inaba, S, Ishibashi, T & Ohno, S 2006, 'Granulocytapheresis in patients with refractory ocular behcet's disease', Journal of Clinical Apheresis, vol. 21, no. 2, pp. 121-128. https://doi.org/10.1002/jca.20076
Namba, Kenichi ; Sonoda, Koh Hei ; Kitamei, Hirokuni ; Shiratori, Kenji ; Ariyama, Akiko ; Iwabuchi, Kazuya ; Onoé, Kazunori ; Saniabadi, Abby R. ; Inaba, Shoichi ; Ishibashi, Tatsuro ; Ohno, Shigeaki. / Granulocytapheresis in patients with refractory ocular behcet's disease. In: Journal of Clinical Apheresis. 2006 ; Vol. 21, No. 2. pp. 121-128.
@article{6fd81d4d6dc9486b9804443df2ff015a,
title = "Granulocytapheresis in patients with refractory ocular behcet's disease",
abstract = "Intraocular inflammation (uveoretinitis) is one major complication of Behcet's disease (BD) and responds poorly to drug therapy. This open prospective study was to assess the efficacy of selective granulocytapheresis in patients with refractory uveoretinitis of BD. Fourteen patients aged 20-56 years were treated. Granulocytapheresis was done with an Adacolumn filled with cellulose acetate leucocyte carries or beads that adsorb granulocytes and monocytes from the blood in the column. Each patient received 5 Adacolumn sessions at one session/week over 5 consecutive weeks. The study was designed to allow each patient to serve as his or her own control. The total numbers of ocular attacks (OA) were monitored for 6 months before and after 5 Adacolumn sessions. The number of OA (mean ± SD) per patient for the 6 months before Adacolumn was 4.21 ± 1.6 and for the 6 months post Adacolumn was 2.93 ± 1.39 (P = 0.0275). Nine patients (64{\%}) improved and 5 did not change or worsened. Further, for a sub-group (n = 7) with duration of BD ≥5 years, the number of OA were 4.71 ± 1.89 for the first 6 months and 2.29 ± 1.38 for the second 6 months (P = 0.0054). The corresponding values for a sub-group (n = 7) with duration of BD<5 years were 3.71 ± 1.25 and 3.57 ± 1.13, indicating that patients with long duration of BD are better responders. We conclude that granulocytapheresis might be effective and safe for patients with refractory ocular BD. Further studies are necessary to fully evaluate the clinical efficacy of granulocytapheresis for BD.",
author = "Kenichi Namba and Sonoda, {Koh Hei} and Hirokuni Kitamei and Kenji Shiratori and Akiko Ariyama and Kazuya Iwabuchi and Kazunori Ono{\'e} and Saniabadi, {Abby R.} and Shoichi Inaba and Tatsuro Ishibashi and Shigeaki Ohno",
year = "2006",
month = "7",
day = "1",
doi = "10.1002/jca.20076",
language = "English",
volume = "21",
pages = "121--128",
journal = "Journal of Clinical Apheresis",
issn = "0733-2459",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Granulocytapheresis in patients with refractory ocular behcet's disease

AU - Namba, Kenichi

AU - Sonoda, Koh Hei

AU - Kitamei, Hirokuni

AU - Shiratori, Kenji

AU - Ariyama, Akiko

AU - Iwabuchi, Kazuya

AU - Onoé, Kazunori

AU - Saniabadi, Abby R.

AU - Inaba, Shoichi

AU - Ishibashi, Tatsuro

AU - Ohno, Shigeaki

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Intraocular inflammation (uveoretinitis) is one major complication of Behcet's disease (BD) and responds poorly to drug therapy. This open prospective study was to assess the efficacy of selective granulocytapheresis in patients with refractory uveoretinitis of BD. Fourteen patients aged 20-56 years were treated. Granulocytapheresis was done with an Adacolumn filled with cellulose acetate leucocyte carries or beads that adsorb granulocytes and monocytes from the blood in the column. Each patient received 5 Adacolumn sessions at one session/week over 5 consecutive weeks. The study was designed to allow each patient to serve as his or her own control. The total numbers of ocular attacks (OA) were monitored for 6 months before and after 5 Adacolumn sessions. The number of OA (mean ± SD) per patient for the 6 months before Adacolumn was 4.21 ± 1.6 and for the 6 months post Adacolumn was 2.93 ± 1.39 (P = 0.0275). Nine patients (64%) improved and 5 did not change or worsened. Further, for a sub-group (n = 7) with duration of BD ≥5 years, the number of OA were 4.71 ± 1.89 for the first 6 months and 2.29 ± 1.38 for the second 6 months (P = 0.0054). The corresponding values for a sub-group (n = 7) with duration of BD<5 years were 3.71 ± 1.25 and 3.57 ± 1.13, indicating that patients with long duration of BD are better responders. We conclude that granulocytapheresis might be effective and safe for patients with refractory ocular BD. Further studies are necessary to fully evaluate the clinical efficacy of granulocytapheresis for BD.

AB - Intraocular inflammation (uveoretinitis) is one major complication of Behcet's disease (BD) and responds poorly to drug therapy. This open prospective study was to assess the efficacy of selective granulocytapheresis in patients with refractory uveoretinitis of BD. Fourteen patients aged 20-56 years were treated. Granulocytapheresis was done with an Adacolumn filled with cellulose acetate leucocyte carries or beads that adsorb granulocytes and monocytes from the blood in the column. Each patient received 5 Adacolumn sessions at one session/week over 5 consecutive weeks. The study was designed to allow each patient to serve as his or her own control. The total numbers of ocular attacks (OA) were monitored for 6 months before and after 5 Adacolumn sessions. The number of OA (mean ± SD) per patient for the 6 months before Adacolumn was 4.21 ± 1.6 and for the 6 months post Adacolumn was 2.93 ± 1.39 (P = 0.0275). Nine patients (64%) improved and 5 did not change or worsened. Further, for a sub-group (n = 7) with duration of BD ≥5 years, the number of OA were 4.71 ± 1.89 for the first 6 months and 2.29 ± 1.38 for the second 6 months (P = 0.0054). The corresponding values for a sub-group (n = 7) with duration of BD<5 years were 3.71 ± 1.25 and 3.57 ± 1.13, indicating that patients with long duration of BD are better responders. We conclude that granulocytapheresis might be effective and safe for patients with refractory ocular BD. Further studies are necessary to fully evaluate the clinical efficacy of granulocytapheresis for BD.

UR - http://www.scopus.com/inward/record.url?scp=33750113043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750113043&partnerID=8YFLogxK

U2 - 10.1002/jca.20076

DO - 10.1002/jca.20076

M3 - Article

C2 - 16395727

AN - SCOPUS:33750113043

VL - 21

SP - 121

EP - 128

JO - Journal of Clinical Apheresis

JF - Journal of Clinical Apheresis

SN - 0733-2459

IS - 2

ER -